1.Intralesional and topical treatments for Peyronie's disease: a narrative review of current knowledge.
Antonio MINORE ; Loris CACCIATORE ; Fabrizio PRESICCE ; Andrea IANNUZZI ; Antonio TESTA ; Gianluigi RASO ; Rocco PAPALIA ; Marco MARTINI ; Roberto Mario SCARPA ; Francesco ESPERTO
Asian Journal of Andrology 2025;27(2):156-165
Peyronie's disease (PD) presents a multifaceted challenge in contemporary urological practice, marked by penile deformity, pain, and the potential for erectile dysfunction. We meticulously explored the existing literature of intralesional/topical interventions, aiming to provide clinicians with a nuanced understanding of available options for comprehensive PD management. To conduct this review, we performed a systematic search using the PubMed, Scopus, and ScienceDirect databases, including the keywords of combination of the "Peyronie's disease/plastic induration of the penis (PIP) and intralesional/topical treatments". The study selection was based on adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, resulting in the inclusion of 16 articles. We delve into the effectiveness and safety profiles of collagenase Clostridium histolyticum (CCH), interferon, platelet-rich plasma (PRP), hyaluronic acid, botulinum toxin, stem cell, extracorporeal shock wave therapy (ESWT), and traction therapy, assessing their impact on penile curvature, length improvement, and patient-reported symptoms and outcomes. The best options evaluated are intralesional injections of CCH and penile traction devices, alone or in combination. Despite PD remains a challenge for urologists, the objective of this review is to contribute to the evolving landscape of PD management, fostering informed decision-making, and personalized care for individuals grappling with this challenging condition.
Humans
;
Male
;
Administration, Topical
;
Botulinum Toxins/administration & dosage*
;
Extracorporeal Shockwave Therapy
;
Hyaluronic Acid/administration & dosage*
;
Injections, Intralesional
;
Interferons/administration & dosage*
;
Microbial Collagenase/administration & dosage*
;
Penile Induration/therapy*
;
Platelet-Rich Plasma
;
Stem Cell Transplantation
;
Traction
2.Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups
Giorgio BOGANI ; Giovanni APOLONE ; Antonino DITTO ; Giovanni SCAMBIA ; Pierluigi Benedetti PANICI ; Roberto ANGIOLI ; Sandro PIGNATA ; Stefano GREGGI ; Paolo SCOLLO ; Mezzanzanica DELIA ; Massimo FRANCHI ; Fabio MARTINELLI ; Mauro SIGNORELLI ; Salvatore LOPEZ ; Violante Di DONATO ; Giorgio VALABREGA ; Gabriella FERRANDINA ; Innocenza PALAIA ; Alice BERGAMINI ; Luca BOCCIOLONE ; Antonella SAVARESE ; Fabio GHEZZI ; Jvan CASARIN ; Ciro PINELLI ; Vito TROJANO ; Vito CHIANTERA ; Giorgio GIORDA ; Francesco SOPRACORDEVOLE ; Mario MALZONI ; Giovanna SALERNO ; Enrico SARTORI ; Antonia TESTA ; Gianfranco ZANNONI ; Fulvio ZULLO ; Enrico VIZZA ; Giuseppe TROJANO ; Antonio CHIANTERA ; Francesco RASPAGLIESI
Journal of Gynecologic Oncology 2020;31(6):e92-
Objective:
Coronavirus disease 2019 (COVID-19) has caused rapid and drastic changes in cancer management. The Italian Society of Gynecology and Obstetrics (SIGO), and the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of gynecologist oncologists and to assess the implementation of containment measures against COVID-19 diffusion.
Methods:
The survey consisted of a self-administered, anonymous, online questionnaire. Thesurvey was sent via email to all the members of the SIGO, and MITO groups on April 7, 2020, and was closed on April 20, 2020.
Results:
Overall, 604 participants completed the questionnaire with a response-rate of 70%. The results of this survey suggest that gynecologic oncology units had set a proactive approach to COVID-19 outbreak. Triage methods were adopted in order to minimize in-hospital diffusion of COVID-19. Only 38% of gynecologic surgeons were concerned about COVID-19 outbreak. Although 73% of the participants stated that COVID-19 has not significantly modified their everyday practice, 21% declared a decrease of the use of laparoscopy in favor of open surgery (19%). However, less than 50% of surgeons adopted specific protection against COVID-19. Additionally, responders suggested to delay cancer treatment (10%–15%), and to perform less radical surgical procedures (20%–25%) during COVID-19 pandemic.
Conclusions
National guidelines should be implemented to further promote the safety of patients and health care providers. International cooperation is of paramount importance, as heavily affected nations can serve as an example to find out ways to safely preserve clinical activity during the COVID-19 outbreak.

Result Analysis
Print
Save
E-mail